Friday, September 30, 2022


Biotechnology News Magazine

Blacktrace Launches Particle Works

The new dedicated particle engineering brand

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Blacktrace Holdings Ltd – a world leader in Productizing Science® has announced the launch of Particle Works, a spin out of Dolomite Microfluidics. The official launch of this new brand will take place at the LNP Formulation and Process Development Summit in Boston, MA, from the 12th to 14th April 2022.

Particle Works’ game-changing particle engineering platforms are set to revolutionise the way customers discover, develop and scale-up particle production for a wide range of applications. The brand draws on Blacktrace Holdings’ 20+ years of experience in particle engineering and microfluidic technology to offer novel systems for the consistent and reliable generation of various particle types for use in the medical, biotechnology and materials science industries.

Previously, nanoparticles – such as liposomes, lipid nanoparticles (LNPs) and polymer-based nanoparticles – have been produced using batch methods that are inconsistent and difficult to control, risking damage to encapsulated products and leading to polydisperse particles to produce variable in vivo results.

Particle Works will solve this challenge by using proven and reliable microfluidic technologies to create pioneering systems capable of consistent and tuneable particle generation. This will enable the manufacturing process to be more stable and efficient, with a lower chance of particle damage, further reducing time of development cycles compared to traditional batch methods. The brand will initially focus on enhancing drug encapsulation and vaccine delivery, opening previously inaccessible extremely performant and precision solutions to its customers.

Lee Jeffries, Managing Director of Particle Works, explained: “As leaders in the field of particle technology, we understand the needs of our customers, and Particle Works is the direct result of the growing demand for reliable and scalable solutions for nanoparticle production.

From formulation, screening and process optimisation to scale-up manufacturing, Particle Works will provide scientists with innovative and automated platforms to speed up their processes, enabling customers to produce nanoparticles with unrivalled precision, consistency and control. This will help to minimise sample use and shorten timelines from discovery to manufacture.”

About Particle Works: Particle Works combines a strong heritage in engineering with scientific knowledge, microfluidic expertise and in-house chip fabrication. We are dedicated to designing and building state-of-the-art particle engineering platforms, paving the way to particle perfection.

Their technology is used in a wide range of applications, including the production of nanoparticle-based vaccines, medicines, and therapeutics. Building on the tried and tested technology of Dolomite Microfluidics, Particle Works’ platforms enable scientists to formulate particles faster, ensuring they are ready for their next breakthrough and the scale up of discoveries. We have been at the forefront of this rapidly changing science, listening and adapting as our customers’ needs have evolved. With Particle Works, we bring you a focused brand where together we can unlock the true power of particles.

Particle Works is part of Blacktrace Holdings Limited – a world leader in Productizing Science™ – and is based in Royston (near Cambridge) UK. We have offices in the USA, Japan and Vietnam, and worldwide distributors offering technical assistance and support.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine